Company / Return on Equity (ROE)
Gilead Sciences Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
37.5%
FY2025
5-year range
0.6% / 37.5%
FY2021-FY2025
Trend
+1411.3%
vs FY2024
Sector context
#10 of 190
Health Care
What the data says
Return on Equity (ROE) changed +1411% YoY in FY2025, a notable deviation from the 9-year average annual change of +1036%.
Based on SEC 10-K filings.
37.5% in FY2025 with a 5-year CAGR of +36.8%. Top quartile in the Health Care sector.
Improved from 27.3% to 37.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +36.9pp
- 5-Year Change
- +36.8pp
- 10-Year Change
- -
Sector benchmark
Top 5% in Health CareTop 5% of 190This company 37.5% Sector average -50.3%
▼
+174.5% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 1411.3% year-over-year.
- Currently 87.8pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 37.5% | +1411.3% |
| FY2024 | 2.5% | -90.9% |
| FY2023 | 27.3% | +4600.0% |
| FY2022 | 0.6% | -97.7% |
| FY2021 | 25.6% | +3658.8% |
| FY2020 | 0.7% | -96.7% |
| FY2019 | 20.5% | -67.4% |
| FY2018 | 63.1% | -28.7% |
| FY2017 | 88.6% | +38.3% |
| FY2016 | 64.1% | -34.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026